Derfor lykkes vi i Norge

GE Healthcare ASMedical Diagnostics NorwayWho are we today?What are our success criteria?

2 /This is GE Healthcare

Who we are: GE business segments

Aviation

Energy

EnterpriseSolutions

Water

Oil & Gas

CommercialFinance

GE Money

CorporateTreasury

Transportation

Healthcare

TechnologyInfrastructure

EnergyInfrastructure

GECapital

NBCUniversal

GE is Imagination at Work - a diversified technology, media and financial services company focused on solving some of the world's toughest problems. With products and services ranging from aircraft engines, power generation, water processing and security technology to medical imaging, business and consumer financing, media content and industrial products, we serve customers in more than 100 countries and employ more than 320,000 people worldwide.


Broad solutions for healthcare

Medical Diagnostics Electronic

medical records

Diagnostic imaging &Surgery

Discovery tools

Integrated admin. & clinical

ClinicalSystems

Picture Archiving System (PACS)

Protein & cell sciences

Clinical tissue biomarkers

Broad-based Diagnostics

LifeSciences

InformationTechnology


GE Healthcare•$17B global business unit of GE•$1B+/year in R&D investment

–Over 2,000 research scientists–Nearly 1,000 PhDs–Multiple disciplines–45 different nationalities

•44.000 employees


Medical Diagnostics (~4500 employees)•The only Pharmaceutical unit in GE•World leader in contrast agents and nuclear medicine products for diagnostic imaging across all modalities.


GE Healthcare AS – Norwegian branch of Medical DiagnosticsMilestones

The exceptional R&D environment that has emerged in Norway since 1874 will continue to play an important role in the development of new products for diagnosis, treatment and prevention of disease. This position was continued with the merger between Nycomed and Amersham International in 1997 - further strengthened under GE Healthcare from 2004

Pharmacist Morten NyegaardFounder of Nyegaard & Co,later Nycomed, in 1874

Nycomed’s first X-ray contrast medium, a copyprep. reg.1934

Nycomed develops world’s first non-ionic X-ray contrast medium in collaboration with Professor Torsten Almén of Lund, Sweden

Omnipaque, 2nd generation non-ionicX-ray contrast medium, for many years ranked among the top 10 pharma-ceutical products sold world-wide.


GE Healthcare AS

• Total revenues (incl exports): $ 1,0 billion • In market sales: $15,5 million• R&D 55 $ (ex 5.11) 136’ $ (08’) ( approx. 1 mill $ 09’)• approx. 200 employees

GEHC total no of employees: 1300 - Largest Pharma player in Norway

Lindesnes site (Primary manuf. 350 employees)

Oslo site (Sec. manuf., R&D, 650 employees)


Key promoted brands

Launched 2000First agent to

identify Parkinson’s Disease

Launched 1996Myocardial perfusion

Launched 1993Non-ionic MRIAll disease areas

Launched 1982Global Gold standardAll disease areas

Launched 1993ONLY Iso-Osmolar

mediaAll disease areas

Product Description ~ Annual Rev $m

>500m

>700m

>300m

>180m

>40m


So what’s makes a success? (I)

•Key competences – focus•Decisiveness (privately owned at the time)•Available funding•The right product area – niche(?)•The right product opportunity - IPR•Key competence - develop


So what’s makes a success? (II)

•Right strategy (build from strength)– Leverage partnerships

(Schering/Daiichi/Sterling) & local strength– Transition to own presence (Schering-Sterling) – Focus on core competencies (CM…)– Continuous improvements (Lindesnes/primary

production – retain competitiveness)– Long term R&D strategy and continuous

investments (build capacity + feed pipeline)– Business Dvlp – M&A

X


Predict

Gene Assay

MolecularDiagnostics

Predict & Prevent Disease …

Detect

ProteinIn Vitro(IVD)

Pinpoint

Imaging

Imaging, IVD

Track and Verify

MolecularImaging

Prevent/Treat

MolecularTherapeutics

The Future … Molecular Medicine

MolecularTherapeutics

MolecularImaging

MolecularDiagnostics


Diagnose and treat before symptoms appearProvide treatments tailored to individual’s genetic makeupFocusing on cancer, heart disease and Alzheimer'sCollaborating with leading pharmaceutical companies and medical researchersGE in best position to grow and leverage

Molecular Medicine


Portfolio spans modalities and diseases

CardiologyOncologyNeurologyUrology

Optical Imaging

TargetedSPECT PETMRI SPECTX-Ray/CT

Anatomy Function Perfusion Viability Metabolism

Contrast Media Molecular Imaging


Post GE – why Norway?

•Focus on core competencies (CM + MI) feed product pipeline•Continuous improvements (Lindesnes/primary production – maintain competitiveness) Available competence – limitations NorwayAvailable funding need competitive environment (R&D/technology developments: incentives) – global competition

Norway need to stay competitive – do’s & don’ts:– Cost levels invest in high tech/focus on cost drivers– Funding develop incentives – establish competitive advantages – commercialization is key– Competence education + “brain” import simplification– Do not create obstacles harmonized rules & regulations

Takk!

Spørsmål?


What is Pharma?

• $650B global market• $500MM - $1B sales per year• Highly regulated industry from

development through marketing• General patent life ~ 20 yrs• Average drug development 10 – 15 yrs

at a cost of greater than $1B* • Generally thought of as encompassing

therapeutic drugs, both branded and generic

• Chronic administration

Therapeutics Diagnostics• $7B global market• Sub-segment of the pharmaceutical

industry (“specialty pharma”)• $50 - $200MM sales per year• Drugs used to aid in diagnostic

imaging procedures that highlight organs, tissues and processes in the body

• Acute administration• Only 2 products approved in past 10

years• POS ranges from 16% phase 1 to

50% phase 3*Includes costs of failed compounds


Fra Nyegaard & Co til GE Healthcare

1874 Morten Nyegaard, cand pharm

1890 Nyegaard & Co (Nyco)1986 Nycomed AS1992 Nycomed Imaging AS1997 Nycomed Amersham

Imaging AS2001 Amersham Health AS2004 GE Healthcare